NCT04873258 Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
| NCT ID | NCT04873258 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Richmond Research Institute |
| Condition | Healthy |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2019-09-27 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2019-09-27 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A generic screening study to establish structural and/or functional baselines of specific organs.
Eligibility Criteria
Inclusion Criteria: 1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent. 2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations. 3. An understanding, ability and willingness to fully comply with project procedures and restrictions. For PART B only: 1\. With a known history of MASLD as evidenced either of: 1. GP diagnosis on HCF 2. Documented Fibroscan or liver US demonstrating MASLD Exclusion Criteria: 1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other) 2. Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease) 3. Alcohol consumption \>30 units per week 4. An Implanted cardiac devices
Contact & Investigator
Jorg Taubel, MD
PRINCIPAL INVESTIGATOR
Richmond Pharmacology Limited
Frequently Asked Questions
Who can join the NCT04873258 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04873258 currently recruiting?
Yes, NCT04873258 is actively recruiting participants. Contact the research team at grants@richmondresearchinstitute.org for enrollment information.
Where is the NCT04873258 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT04873258 clinical trial?
NCT04873258 is sponsored by Richmond Research Institute. The principal investigator is Jorg Taubel, MD at Richmond Pharmacology Limited. The trial plans to enroll 2,000 participants.